Literature DB >> 31680038

Secondary in-hospital epidemiological investigation after an outbreak of Pseudomonas aeruginosa ST357.

Toshihito Mihara1, Takeshi Kimura2, Kyoko Momiyama3, Atsushi Kainuma4, Koichi Akiyama5, Junya Ohara6, Keita Inoue7, Mao Kinoshita8, Masaru Shimizu9, Kiyoshi Moriyama10, Naohisa Fujita11, Teiji Sawa12.   

Abstract

The secondary in-hospital epidemiological investigation for drug-resistant Pseudomonas aeruginosa infections was conducted to evaluate the in-hospital situation and identify any associations between exoenzyme genotypes and other genotypes and antimicrobial resistance characteristics, at the University Hospital in Kyoto, Japan, following a reported outbreak of antimicrobial-resistant P. aeruginosa ST357 between 2005 and 2014. Twelve of the 546 P. aeruginosa isolates collected during the follow-up period were resistant to more than two classes of antimicrobials. All isolates were resistant to fluoroquinolones and 8 (66.7%) showed carbapenem resistance. None of the isolates fulfilled the clinical criteria for multidrug-resistant P. aeruginosa. All isolates were metallo-β-lactamase test-negative. Among five exoS (-)exoU (+) isolates, three possessing a class 1 integron with gene cassette aadB + cmlA6 were classified as ST357, and one isolate containing a class 1 integron with aacA31 was ST235. Collectively, the second survey results confirm that the initial outbreak is currently undergoing convergence. By combining data from the first and second surveys, we showed that prevalent STs such as ST357 and ST235 are associated with fluoroquinolone resistance, class 1 integron-associated resistance to β-lactams and aminoglycosides, and cytotoxic exoU (+) genotypes. With the current worldwide spread of ST357 and ST235 isolates, it is important to evaluate epidemiological trends for high-risk P. aeruginosa isolates by continuous hospital monitoring.
Copyright © 2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Epidemiology; Integron; Multilocus sequence typing; Pseudomonas aeruginosa; Type III secretion system; exoU

Year:  2019        PMID: 31680038     DOI: 10.1016/j.jiac.2019.09.014

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  5 in total

1.  Antibiotic-resistant organisms establish reservoirs in new hospital built environments and are related to patient blood infection isolates.

Authors:  Kimberley V Sukhum; Erin P Newcomer; Candice Cass; Meghan A Wallace; Caitlin Johnson; Jeremy Fine; Steven Sax; Margaret H Barlet; Carey-Ann D Burnham; Gautam Dantas; Jennie H Kwon
Journal:  Commun Med (Lond)       Date:  2022-06-01

Review 2.  Molecular diversity of extended-spectrum β-lactamases and carbapenemases, and antimicrobial resistance.

Authors:  Teiji Sawa; Kunihiko Kooguchi; Kiyoshi Moriyama
Journal:  J Intensive Care       Date:  2020-01-28

3.  Whole Genome Sequencing of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Resistant Pseudomonas aeruginosa Isolated from a Blood Stream Infection Reveals VEB and Chromosomal Metallo-Beta Lactamases as Genetic Determinants: A Case Report.

Authors:  Aisha M Alamri; Somayah Alfifi; Yasser Aljehani; Amani Alnimr
Journal:  Infect Drug Resist       Date:  2020-11-23       Impact factor: 4.003

4.  Whole Genome Multi-Locus Sequence Typing and Genomic Single Nucleotide Polymorphism Analysis for Epidemiological Typing of Pseudomonas aeruginosa From Indonesian Intensive Care Units.

Authors:  Manisha Goyal; Andreu Coello Pelegrin; Magali Jaillard; Yulia Rosa Saharman; Corné H W Klaassen; Henri A Verbrugh; Juliëtte A Severin; Alex van Belkum
Journal:  Front Microbiol       Date:  2022-07-14       Impact factor: 6.064

5.  Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa.

Authors:  María José Contreras-Gómez; José R W Martinez; Lina Rivas; Roberto Riquelme-Neira; Juan A Ugalde; Aniela Wozniak; Patricia García; José M Munita; Jorge Olivares-Pacheco; Manuel Alcalde-Rico
Journal:  Front Pharmacol       Date:  2022-10-03       Impact factor: 5.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.